About Glaxosmithkline Holdings (americas) Inc.
GlaxoSmithKline (GSK) gives anxiety, asthma, and other ailments the ax. One of the top five pharmaceutical firms in the world, GSK's bestsellers include respiratory, neurological, cardiovascular and dermatology drugs, as well as vaccines and antivirals and consumer healthcare products. It boasts four billion-dollar drugs: Advair/Seretide, its stalwart asthma medication; Relvar/Breo Ellipta, a chronic obstructive pulmonary disease treatment; and two HIV medications, Triumeq and Tivicay. In the consumer healthcare business, GSK racks up big sales from its Sensodyne toothpaste brand, joint-pain relief medicine Voltaren, and fever relief medicine Panadol. Based in the UK, GSK has customers across the globe.
GSK operates through three primary segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. Pharmaceuticals is the largest by far, pulling more than half of revenue.
The Pharmaceuticals division develops and manufactures drugs for a wide variety of purposes, but with a specialism in drugs that treat respiratory disease and HIV. Asthma medication Advair has been GSK's primary money spinner for many years although it faces intensifying competition from biosimilars and generics. HIV drugs Trimueq and Tivicay are GSK's next biggest, while other respiratory drugs include Relvar/Breo Ellipta, Ventolin, and Flixotide. The division's R&D activity focuses on respiratory, HIV/infectious illnesses, oncology, and immuno-inflammation medicine.
GSK's Consumer Healthcare segment generates more than 25% of sales and produces products in the oral health, wellness, nutrition, and skin health categories. Its major brands include Advil, Voltaren, Centrum, Caltrate and Otrivin. In 2019, GSK combined its Consumer Healthcare segment with the consumer health division of Pfizer to create an over-the-counter giant, adding brands such as Advil, Centrum, and Robitussin.
The Vaccines segment has around 40 pediatric, adolescent, adult, and travel vaccines on the market in more than 160 countries. Meningitis vaccines Bexsero and Menveo are its biggest earner, followed by flu vaccine Fluarix and Shingles vaccine Shingrix. Sales of vaccines account for around 20% of GSK's annual sales.
Headquartered in London, GSK has an extensive network of manufacturing sites and R&D centres in about 35 countries and major R&D centers are located in the UK, the US, Belgium, and China. It has presence in approximately 150 countries.
The US is GSK's largest market at some 40% of sales. Europe generates a quarter.
Sales and Marketing
GSK sells its products through a small number of wholesalers in addition to hospitals, pharmacies, physicians and other groups. Sales to the three largest wholesalers amounted to approximately 80% of the sales of the US Pharmaceuticals and Vaccines business.
Note: Growth rates may differ after conversion to US dollars.
GSK's revenue has been rising in the last five years with an overall growth of 41% between 2015 and 2019. Its net income, after a colossal drop in 2016, redeemed itself yearly. 2019's net income is 45% lower compared to 2018's. Group turnover for the year increased 10% from $33.8 billion in 2018 to £33.8 billion in 2019, with growth delivered by Vaccines and Consumer Healthcare, and Pharmaceuticals flat at CER. Pro-forma turnover growth for the Group was 4% CER. The company's net income was £4.6 billion in 2019, a 28% increase from the previous year. This was primarily due to the larger turnover, and a positive operating income compared to the operating loss in the previous year.
GSK's cash and bank overdrafts at end of 2019 totaled £4.8 billion, a £744 million increase from 2018. Operating activities generated £8 billion while investing activities used 5.4 billion. Financing activities used another £1.8 billion. GSK's main cash uses in 2019 were for capital expenditures and dividends paid.
GSK's strategy is to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people. The company also works with world-leading experts and form strategic partnerships to complement its existing capabilities.
GSK prepares for the future by investing in R&D and new products. Since announcing its new approach to R&D in 2018, the company has made significant progress to strengthen its pipeline, particularly in oncology. It now has 39 medicines and 15 vaccines in the pipeline, and in 2019 it had three major approvals, eight regulatory submissions, six positive read-outs from pivotal studies and has progressed four new assets into pivotal studies. During 2019 GSK also completed transactions with Tesaro and with Merck KGaA, further strengthening its position in oncology, and initiated alliances to build out platform technologies, in genomics with the University of California, and in cell therapy with Lyell Immunopharma.
In early 2020, consistent with its strategic priorities and previous announcements, GSK started a two-year programme to prepare itself for separation into two new leading companies: New GSK, a biopharma company, with an R&D approach focused on science related to the immune system, use of genetics and new technologies; and a new Consumer Healthcare company with category-leading power brands and innovation based on science and consumer insights.
Mergers and Acquisitions
In early 2019, GlaxoSmithKline acquired US-based oncology pharma company Tesaro in a £4 billion deal. That deal brought the company Tesaro's newly launched PARP inhibitor Zejula for the treatment of ovarian cancer. PARP inhibitors have shown promise in treating certain cancers in combination with other drugs.
1105 N Market St
Wilmington, DE 19801-1216
Phone: 1 (302) 984-6932
Employer Type: Privately Owned
Contract Manager: Meghan Hogan
Administrative Assistant: Carol Mcclinton
Executive Assistant: Shirley Reilly
Employees (This Location): 250
Employees (All Locations): 24,000